Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents

References

• Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399-408
   PubMedGoogle Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34
   PubMed Web of Science ®Google Scholar
• Tsoumani ME, Kalantzi KI, Goudevenos IA, et al. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. Curr Vasc Pharmacol 2012;10:539-49
   PubMed Web of Science ®Google Scholar
• Kalantzi KI, Tsoumani ME, Goudevenos IA, et al. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol 2012;5:319-36
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Papathanasiou A, Goudevenos J, Tselepis AD. Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact. Curr Pharm Des 2009;15:1085-94
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: a systematic review and meta-analysis. BMJ 2008;336:195-8
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13
   PubMed Web of Science ®Google Scholar
• Kalantzi KI, Dimitriou AA, Goudevenos JA, et al. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets 2012;23:121-31
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33
   PubMed Web of Science ®Google Scholar
• Curzen N, Sambu N. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? Heart 2011;97:1433-40
   PubMed Web of Science ®Google Scholar
• Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011;8:547-59
   PubMed Web of Science ®Google Scholar
• Shiva Dindyal S, Kyriakides C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Rec Pat Cardiov Drug Discov 2009;4:6-14
   PubMedGoogle Scholar
• Rizzo M, Corrado E, Patti AM, et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011;12:647-55
   PubMed Web of Science ®Google Scholar
• Jeong Y-H, Hwang J-Y, Kim I-S, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With acute MI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010;3:17-26
   PubMed Web of Science ®Google Scholar
• Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011;4:381-91
   PubMed Web of Science ®Google Scholar
• Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-9
   PubMed Web of Science ®Google Scholar
• Panchal HB, Shah T, Patel P, et al. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis. J Cardiovasc Pharmacol Ther 2013; Jul 19. [Epub ahead of print] PMID: 23872509
   Google Scholar
• Min PK, Jung JH, Ko YG, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007;71:1685-90
   PubMed Web of Science ®Google Scholar
• Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32
   PubMed Web of Science ®Google Scholar
• Lee SW, Ahn JM, Han S, et al. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). Am J Cardiol 2013; Jul 23. doi:pii: S0002-9149(13)01430-6
   Google Scholar
• Chen Y, Zhang Y, Tang Y, et al. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin 2014;30:37-49
   Google Scholar
• Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Tsoumani ME, Kalantzi KI, Dimitriou AA, et al. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. Expert Opin Pharmacother 2012;13:149-58
   PubMed Web of Science ®Google Scholar
• Tsoumani ME, Kalantzi KI, Goudevenos IA, et al. Clopidogrel generic formulations in the era of new antiplatelets. A systematic review. Curr Vasc Pharmacol 2013; Jul 25. [Epub ahead of print] PMID: 23885646
   Google Scholar
• Park KH, Jeong MH, Lee KH, et al. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction. J Cardiol 2013; Sep 5. pii: S0914-5087(13)00229-3
   Google Scholar